Surgical outcomes of robot-assisted super-low anterior resection or robot-assisted rectectomy with transanal anastomosis: a retrospective cohort study

Surgical outcomes of robot-assisted super-low anterior resection or robot-assisted rectal resection with transanal anastomosis: a retrospective cohort study - ROSEMARY study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1010220027

Enrollment

1000

Registered

2022-12-02

Start date

2022-12-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer rectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who underwent R-sLAR or robot-assisted rectal resection with transanal anastomosis (R-ISR or R-TaTME) between January 1, 2020 and December 31, 2021 2) Patients histologically diagnosed with rectal cancer (pap, tub, por, muc, sig, med, or asc)

Exclusion criteria

Exclusion criteria: 1) Patients who indicated their intention to refuse to use the data for this study 2) Other patients who are judged to be inappropriate by the principal investigator or co-investigator

Design outcomes

Primary

Measure	Time frame
Total surgery time and console time Intraoperative bleeding Proportion of transition to laparotomy Occurrence rate of intraoperative adverse events Postoperative hospital stay Severity of residual cancer Rate of all complications within 30 days after surgery Rehospitalization rate within 30 days after surgery Reoperation rate within 30 days after surgery Death rate at discharge 30 day postoperative mortality rate 90 day postoperative mortality rate 3-year local recurrence-free survival (LRFS) 3-year disease-free survival (DFS) 3-year overall survival (OS)	—

Measure

Time frame

Total surgery time and console time Intraoperative bleeding Proportion of transition to laparotomy Occurrence rate of intraoperative adverse events Postoperative hospital stay Severity of residual cancer Rate of all complications within 30 days after surgery Rehospitalization rate within 30 days after surgery Reoperation rate within 30 days after surgery Death rate at discharge 30 day postoperative mortality rate 90 day postoperative mortality rate 3-year local recurrence-free survival (LRFS) 3-year disease-free survival (DFS) 3-year overall survival (OS)

—

Contacts

Public ContactMasaaki Miyo

Osaka Prefectural Hospital Organization Osaka International Cancer Institute

masaaki.miyo@oici.jp+81-6-6945-1181

Outcome results